心脉隆注射液治疗慢性肺源性心脏病50例病例分析(1)
摘 要 目的：研究心脉隆注射液治疗慢性肺源性心脏病的临床疗效。方法：选取100例慢性肺源性心脏病患者随机分为治疗组和对照组各50例。对照组给予常规对症支持治疗，治疗组在对照组的基础上给予心脉隆注射液治疗。比较两组患者临床疗效和不良反应发生情况，以及治疗前、治疗后1周的血浆脑钠肽(BNP)和超声心动图指标包括心率(HR)、心输出量(CO)、心脏指数(CI)、左室短轴缩短率(FS)、左心射血分数(LVEF)的数值变化。结果：治疗组临床疗效明显优于对照组；两组患者治疗前HR、CO、CI、FS、LVEF和血浆BNP比较差异无统计学意义，治疗组治疗后以上指标较治疗前明显改善，且明显优于对照组治疗后；两组患者不良反应比较差异无统计学意义。结论：心脉隆注射液临床疗效显著，可有效改善心功能，且不良反应少。
关键词 心脉隆注射液 慢性肺源性心脏病 脑钠肽
中图分类号：R286； R541.5 文献标识码：B 文章编号：1006-1533(2015)21-0036-03
Analysis of Xinmailong injection for the treatment of 50 cases of patients with chronic pulmonary heart disease*
SHI Changli**， ZHU Jieyan， DING Yuemei
(Department of Respiration， The First Hospital of Jindezhen， Jindezhen 333000， China)
ABSTRACT Objective： To discuss the clinical efficacy of Xinmailong injection in the treatment of pulmonary heart disease. Methods： One hundred cases of patients with pulmonary heart disease were randomly divided into a treatment group and a control group with 50 cases each. All the patients were given conventional symptomatic treatment， and the treatment group was given Xinmailong injection in addition. The clinical efficacy and adverse reactions were compared， and the changes of BNP， HR， CO， CI， FS， LVEF were also compared before and one week after the treatment. Results： The clinical efficacy was significantly better in the treatment group than in the control group. The comparison of HR， CO， CI， FS， LVEF and BNP between two groups showed no significant difference before the treatment， however these indexes were significantly improved in the treatment group and better than in the control group after the treatment. The differences of adverse reactions between two groups had not statistically significance. Conclusion： Xinmailong injection has good clinical efficacy and less adverse reaction and can improve the heart function.
KEY WORDS Xinmailong injection； chronic pulmonary heart disease； BNP
慢性肺源性心脏病又称肺心病，是呼吸内科常见病和多发病之一，发病率高，致残率高，给患者及其家庭、社会等带来沉重负担。心脉隆注射液为我国近年来自主研发的一种临床治疗新药，具有强心、利尿、降低肺动脉压力等作用，其用药安全，副作用少。大量文献表明，心脉隆注射液治疗心力衰竭安全、有效[1]。我院针对慢性肺源性心脏病患者采用心脉隆注射液治疗，临床疗效显著。
1 资料与方法
1.1 一般资料
选取2014年6月-2015年6月我院呼吸内科收治的肺源性心脏病患者，随机分为治疗组和对照组各50例。治疗组中男29例，女性21例，年龄51～78，平均年龄(58.4±6.8)岁；按照美国纽约心脏病学会心功能标准分级：Ⅱ级10例，Ⅲ级28例，Ⅳ级12例；原发病：慢性阻塞性肺病35例，支气管哮喘5例，支气管扩张2例，其他8例。对照组中男30例，女性20例，年龄52～79，平均年龄(59.1±5.9)岁；心功能分级：Ⅱ级11例，Ⅲ级30例，Ⅳ级9例；原发病：慢性阻塞性肺病33例，支气管哮喘6例，支气管扩张4例，其他7例。两组患者性别、年龄、病情等一般资料比较差异无统计学意义(P>0.05)，具有可比性。
1.2 纳入标准
①符合第8届全国肺心病会议制定的诊断标准[2]；②年龄50～80岁；③处于肺心病急性加重期；④合并心力衰竭。, http://www.100md.com(施昌礼 朱捷燕 丁月梅)
关键词 心脉隆注射液 慢性肺源性心脏病 脑钠肽
中图分类号：R286； R541.5 文献标识码：B 文章编号：1006-1533(2015)21-0036-03
Analysis of Xinmailong injection for the treatment of 50 cases of patients with chronic pulmonary heart disease*
SHI Changli**， ZHU Jieyan， DING Yuemei
(Department of Respiration， The First Hospital of Jindezhen， Jindezhen 333000， China)
ABSTRACT Objective： To discuss the clinical efficacy of Xinmailong injection in the treatment of pulmonary heart disease. Methods： One hundred cases of patients with pulmonary heart disease were randomly divided into a treatment group and a control group with 50 cases each. All the patients were given conventional symptomatic treatment， and the treatment group was given Xinmailong injection in addition. The clinical efficacy and adverse reactions were compared， and the changes of BNP， HR， CO， CI， FS， LVEF were also compared before and one week after the treatment. Results： The clinical efficacy was significantly better in the treatment group than in the control group. The comparison of HR， CO， CI， FS， LVEF and BNP between two groups showed no significant difference before the treatment， however these indexes were significantly improved in the treatment group and better than in the control group after the treatment. The differences of adverse reactions between two groups had not statistically significance. Conclusion： Xinmailong injection has good clinical efficacy and less adverse reaction and can improve the heart function.
KEY WORDS Xinmailong injection； chronic pulmonary heart disease； BNP
慢性肺源性心脏病又称肺心病，是呼吸内科常见病和多发病之一，发病率高，致残率高，给患者及其家庭、社会等带来沉重负担。心脉隆注射液为我国近年来自主研发的一种临床治疗新药，具有强心、利尿、降低肺动脉压力等作用，其用药安全，副作用少。大量文献表明，心脉隆注射液治疗心力衰竭安全、有效[1]。我院针对慢性肺源性心脏病患者采用心脉隆注射液治疗，临床疗效显著。
1 资料与方法
1.1 一般资料
选取2014年6月-2015年6月我院呼吸内科收治的肺源性心脏病患者，随机分为治疗组和对照组各50例。治疗组中男29例，女性21例，年龄51～78，平均年龄(58.4±6.8)岁；按照美国纽约心脏病学会心功能标准分级：Ⅱ级10例，Ⅲ级28例，Ⅳ级12例；原发病：慢性阻塞性肺病35例，支气管哮喘5例，支气管扩张2例，其他8例。对照组中男30例，女性20例，年龄52～79，平均年龄(59.1±5.9)岁；心功能分级：Ⅱ级11例，Ⅲ级30例，Ⅳ级9例；原发病：慢性阻塞性肺病33例，支气管哮喘6例，支气管扩张4例，其他7例。两组患者性别、年龄、病情等一般资料比较差异无统计学意义(P>0.05)，具有可比性。
1.2 纳入标准
①符合第8届全国肺心病会议制定的诊断标准[2]；②年龄50～80岁；③处于肺心病急性加重期；④合并心力衰竭。, http://www.100md.com(施昌礼 朱捷燕 丁月梅)